Fernando Gamarra, MD
Gastroenterology · Clinton Twp, MINPI 1457473654
Payments from drug & device makers
Across 747 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$869
- Sanofi$519
- plus $4K from 32 others
What the payments were for
- Food & beverage$13,766100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 182 | $3,562 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 90 | $1,700 |
| Johnson & Johnson | 92 | $1,508 |
| Takeda Pharmaceuticals U.S.A., Inc. | 76 | $1,352 |
| Pfizer | 57 | $869 |
| Sanofi | 23 | $519 |
| QOL Medical, LLC | 24 | $504 |
| Ardelyx, Inc. | 28 | $504 |
| Bristol Myers Squibb | 27 | $437 |
| Gilead | 28 | $425 |
| Intercept Pharmaceuticals, Inc. | 15 | $351 |
| Braintree Laboratories, Inc. | 17 | $337 |
| Ferring Pharmaceuticals Inc. | 11 | $207 |
| Regeneron Healthcare Solutions, Inc. | 9 | $190 |
| Lilly USA, LLC | 6 | $138 |
| Daiichi Sankyo Inc. | 6 | $121 |
| Aimmune Therapeutics, Inc. | 6 | $114 |
| Merck | 6 | $108 |
| Vivus LLC | 5 | $91 |
| Nestle Healthcare Nutrition Inc. | 5 | $77 |
| Fresenius Kabi USA, LLC | 3 | $75 |
| Celltrion USA Inc. | 3 | $69 |
| Evoke Pharma, Inc. | 5 | $63 |
| Novo Nordisk | 3 | $56 |
| Redhill Biopharma Inc. | 2 | $51 |
| Ipsen Biopharmaceuticals, Inc | 2 | $50 |
| Madrigal Pharmaceuticals | 2 | $43 |
| Mylan Institutional Inc. | 2 | $43 |
| Medtronic | 2 | $30 |
| Capsovision, Inc. | 2 | $28 |
| Organon | 1 | $25 |
| Amgen | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Shionogi Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Echosens North America, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Romark Laboratories, LC | 1 | $14 |
How this compares
$13,766 in reported general payments places this provider in the 80th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 35 | $906,117 |
| SucraidSacrosidase | 14 | $195,059 |
| RinvoqUpadacitinib | 12 | $71,309 |
| ZenpepLipase/Protease/Amylase | 12 | $65,837 |
| LinzessLinaclotide | 49 | $38,769 |
| CreonLipase/Protease/Amylase | 12 | $25,712 |
| Mesalamine | 38 | $23,119 |
| Lubiprostone | 43 | $8,822 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 39 | $6,192 |
| Omeprazole | 205 | $3,294 |
| Pantoprazole Sodium | 118 | $2,586 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 138 | $2,446 |
| Sucralfate | 25 | $947 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 41 | $884 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 46 | $851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,508 | $906,11735 claims |
| QOL Medical, LLCSucraid | $504 | $195,05914 claims |
| AbbVieRinvoq, Linzess, Creon | $3,562 | $135,79073 claims |
| Aimmune Therapeutics, Inc.Zenpep | $114 | $65,83712 claims |
| Braintree Laboratories, Inc.Sutab | $337 | $6,19239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 497 gastroenterology providers in Michigan.
Other gastroenterology in Clinton Twp
- Allan CoatesWyoming$5.9M
- Ronald FogelChesterfield$5.1M
- Stuart GordonDetroit$4.3M
- Jeffery BerinsteinAnn Arbor$3.3M
- Najm SoofiYpsilanti$2.6M
- Peter HigginsAnn Arbor$2.4M
- Partha NandiTroy$1.4M
- Frederick AskariAnn Arbor$1.4M
- Reena SalgiaDetroit$1.3M
- Kimberly BrownDetroit$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.